# Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment

> **NCT04169841** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Centre Georges Francois Leclerc** · enrollment: 270 (estimated)

## Conditions studied

- Immunotherapy

## Interventions

- **DRUG:** olaparib, durvalumab, tremelimumab

## Key facts

- **NCT ID:** NCT04169841
- **Lead sponsor:** Centre Georges Francois Leclerc
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-10
- **Primary completion:** 2027-08-10
- **Final completion:** 2027-08-10
- **Target enrollment:** 270 (ESTIMATED)
- **Last updated:** 2024-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04169841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04169841, "Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT04169841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*